Analyses of fluoroquinolones and Clostridium difficile-associated diarrhoea in tuberculosis patients

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 3, 2009, Pages 341-346

  Chang, Kwok Chiu ^a,d   Leung, C C ^a   Yew, W W ^b   Lam, F M ^b   Ho, P L ^c   Chau, C H ^b   Cheng, V C C ^c   Yuen, K Y ^c  

^a DEPARTMENT OF HEALTH   (Hong Kong)

^b GRANTHAM HOSPITAL   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d Wanchai Chest Clinic   (Hong Kong)

Author keywords

Clostridium difficile; Diarrhoea; Fluoroquinolones; Rifampicin; Tuberculosis

Indexed keywords

ALBUMIN; AMINOGLYCOSIDE DERIVATIVE; CARBAPENEM; CEPHALOSPORIN DERIVATIVE; ETHAMBUTOL; ISONIAZID; MACROLIDE; METRONIDAZOLE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE INFECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NOSE FEEDING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS; TUBERCULOSIS; UNIVARIATE ANALYSIS;

AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM INFECTIONS; COMORBIDITY; DIARRHEA; ENTERAL NUTRITION; FEMALE; FLUOROQUINOLONES; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; TUBERCULOSIS, PULMONARY;

EID: 62349102110     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Johnson S, Gerding D N. Clostridium difficile-associated diarrhoea. Clin Infect Dis 1998; 26: 1027-1036.
2. Bignardi G E. Risk factors for Clostridium difficile infection. J Hosp Infect 1998; 40: 1-15.
3. Starr J M, Martin H, McCoubrey J, Gibson G, Poxton I R. Risk factors for Clostridium difficile colonisation and toxin production. Age Ageing 2003; 32: 657-660.
4. Pepin J, Saheb N, Coulombe M A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhoea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
5. Starr J. Clostridium difficile-associated diarrhoea: diagnosis and treatment. BMJ 2005; 331: 498-501.
6. Crofton J, Choculet P, Maher D. WHO report: guidelines for the management of drug-resistant tuberculosis. Geneva, Switzerland: WHO/TB/1996-210. WHO, 1997.
7. Yew W W, Chan C K, Leung C C, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124: 1476-1481.
8. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003; 3: 432-442.
9. Marra F, Marra C A, Moadebi S, et al. Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005; 128: 1406-1413.
10. McCusker M E, Harris A D, Perencevich E, Roghmann M C. Fluoroquinolone use and Clostridium difficile-associated diarrhoea. Emerg Infect Dis 2003; 9: 730-733.
11. Muto C A, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26: 273-280.
12. Loo V G, Poirier L, Miller M A, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhoea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-2449.
13. Kazakova S V, Ware K, Baughman B, et al. A hospital outbreak of diarrhoea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006; 166: 2518-2524.
14. McFarland L V. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 40-48.
15. Migliori G B, Loddenkemper R, Blasi F, Raviglione M C. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is 'science' enough to tackle the epidemic? Eur Respir J 2007; 29: 423-427.
16. Riley T V. Clostridium difficile: a pathogen of the nineties. Eur J Clin Microbiol Infect Dis 1998; 17: 137-141.
17. Thomas C, Stevenson M, Williamson D J, Riley T V. Clostridium difficile-associated diarrhoea: epidemiological data from Western Australia associated with a modified antibiotic policy. Clin Infect Dis 2002; 35: 1457-1462.
18. Schwaber M J, Simhon A, Block C, Roval V, Ferderber N, Shapiro M. Factors associated with nosocomial diarrhoea and Clostridium difficile- associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000; 19: 9-15.
19. Wilcox M H, Freeman J, Fawley W, et al. Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 54: 168-172.
20. Palmore T N, Sohn S, Malak S F, Eagan J, Sepkowitz K A. Risk factors for acquisition of Clostridium difficile-associated diarrhoea among out-patients at a cancer hospital. Infect Control Hosp Epidemiol 2005; 26: 680-684.
21. McFarland L V. Epidemiology of infectious and iatrogenic nosocomial diarrhoea in a cohort of general medicine patients. Am J Infect Control 1995; 23: 295-305.
22. Simor A E, Yake S L, Tsimidis K. Infection due to Clostridium difficile among elderly residents of a long-term care facility. Clin Infect Dis 1993; 17: 672-678.
23. Gerding D N, Brazier J S. Optimal methods for identifying Clostridium difficile infections. Clin Infect Dis 1993; 16 (Suppl 4): S439-S442.
24. Kyne L, Warny M, Qamar A, Kelly C P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
25. Johnson S, Clabots C R, Linn F V, Olson M M, Peterson L R, Gerding D N. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990; 336: 97-100.
26. Dial S, Alrasadi K, Manonkian C, Hoang A, Menzies D. Risk of Clostridium difficile diarrhoea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004; 171: 33-38.
27. Dial S, Delaney J A, Barkun A N, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.
28. Hong Kong Tuberculosis and Chest Service. Annual report. Hong Kong SAR, China, Department of Health, 2005.
29. Mulligan M E, Miller S D, McFarland L V, Fung H C, Kwok R Y. Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile. Clin Infect Dis 1993; 16 (Suppl 4): S239-S244.
30. Kyne L, Warny M, Qamar A, Kelly C P. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-193.
31. Thadepalli H, Bach V T, Webb D W. Antimicrobial activity of anti-tuberculosis agents against anaerobic bacteria. Chest 1979; 75: 569-570.
32. Jung S W, Jeon S W, Do B H, et al. Clinical aspects of rifampicin-associated pseudomembranous colitis. J Clin Gastroenterol 2007; 41: 38-40.
33. Gerding D N, Johnson S, Peterson L R, Mulligan M E, Silva J Jr. Clostridium difficile-associated diarrhoea and colitis. Infect Control Hosp Epidemiol 1995; 16: 459-477.
34. Nakamura S, Nakashio S, Mikawa M, Yamakawa K, Okumura S, Nishida S. Antimicrobial susceptibility of Clostridium difficile from different sources. Microbiol Immunol 1982; 26: 25-30.
35. Nomura K, Matsumoto Y, Yoshida N, et al. Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin's lymphoma. World J Gastroenterol 2004; 10: 765-766.